The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status

孙艺斐; 杨忠毅; 张勇平; 王明伟; 姚之丰; 薛静; 鲍晓; 杨文涛; 沈镇宙; 邵志敏; 章英剑

doi:10.3969/j.issn.1007-3969.2014.02.008

您当前的位置：

首页 >

文章列表页 >

The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status

更新时间：2025-12-31

- The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status
- China Oncology Vol. 24, Issue 2, Pages: 128-134(2014)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院核医学科，复旦大学上海医学院肿瘤学系,上海,200032
  2. 复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系,上海,200032
  3. 复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.02.008
  CLC：
- Published Online：07 March 2014，
  
  Published：07 March 2014
- 稿件说明：
移动端阅览
孙艺斐,杨忠毅,张勇平,王明伟,姚之丰,薛静,鲍晓,杨文涛,沈镇宙,邵志敏,章英剑.

孙艺斐, 杨忠毅, 张勇平, et al. The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status[J]. China Oncology, 2014, 24(2): 128-134.
孙艺斐,杨忠毅,张勇平,王明伟,姚之丰,薛静,鲍晓,杨文涛,沈镇宙,邵志敏,章英剑. DOI： 10.3969/j.issn.1007-3969.2014.02.008.

孙艺斐, 杨忠毅, 张勇平, et al. The correlation of 18F-fluoroestradiol uptake in patients with breast cancer to in vitro immunohistochemical assay of ER status[J]. China Oncology, 2014, 24(2): 128-134. DOI： 10.3969/j.issn.1007-3969.2014.02.008.

摘要

背景与目的：16α-

F-17β-雌二醇(

F-FES)作为雌激素受体(estrogen receptor

ER)特异性显像剂，可在活体内反映ER的表达状况。本研究主要探讨乳腺癌患者体内

F-FES摄取结果与病理免疫组化的相关性。方法：自行制备

F-FES，入组26例乳腺癌患者(17例原发性乳腺癌，9例复发转移性乳腺癌)，分别进行

F-FES及

F-FDG PET/CT显像，对每例患者进行空心针穿刺或手术治疗，对比相应病灶的免疫组化和

F-FES、

F-FDG摄取结果。结果：96.15%(25/26)的患者

F-FES结果与ER病理免疫组化一致，以

F-FES SUV

max

≥1.5为ER阳性，

F-FES PET/CT显像诊断乳腺癌病灶ER阳性的灵敏度为93.33%，特异度为100%。ER、PR的免疫组化结果与

F-FES的SUV

max

呈明显的正相关；HER-2/Neu的免疫组化结果与

F-FES的SUV

max

呈负相关。结论：

F-FES有望用于全面反映乳腺癌患者全身病灶的ER表达情况，为临床个体化治疗方案的制定提供帮助。

Abstract

Background and purpose: 16α-[18F

]

fluoroestradiol (

F-FES) is an in vivo specific imaging agent for estrogen receptor (ER). We investigated the concordance between tumor ER status as determined by FES-PET and in vitro immunohistochemical assays. Methods:

F-FES was prepared by ourselves. Twenty-six patients were enrolled (17 primary and 9 metastatic/recurrent). Patients underwent both

F-FES and

F-FDG PET/CT. Results: We found good overall agreemen

t (96.15%) between in vitro ER assays and FES-PET. The ER status diagnosis sensitivity of

F-FES was 93.33% and the specificity was 100% when using cut-off value of SUV

max

≥1.5. There was a positive correlation between in vitro ER

PR assays and the SUV

max

F-FES while in vitro HER-2/neu assays correlatived negatively with

F-FES SUV

max

. Conclusion: These results suggested

F-FES may be useful for studying the ER expression of all malignant lesions in patients with breast cancer and guiding individual therapy.

关键词

Keywords

references

Views

2660

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research advances in estrogen receptor low positive early breast cancer

The value of¹⁸F-FDG PET/CT texture analysis in predicting neoadjuvant chemoradiotherapy of locally advanced rectal cancer

Clinical significance of ICAM-1 expression and its correlation with prognosis of triple-negative breast cancer

Dual-phase¹⁸F-FDG coincidence detection SPECT/CT imaging for differential diagnosis of pulmonary lesions

Expression correlation between Efp and Plk3 in estrogen receptor-positive breast cancer

Related Author

Jian ZHANG

Qing GUO

Cheng ZENG

Mingxi LIN

Yizi JIN

徐俊彦

张建平

郑营营

Related Institution

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

复旦大学生物医学影像研究中心

核物理与离子束应用教育部重点实验室

上海分子影像探针工程技术研究中心

上海交通大学附属第六人民医院肿瘤内科

AI问答

⁰